As quadrivalent meningococcal conjugate vaccines offer the broadest, most durable and most effective protection, they are the preferred option over polysaccharide vaccines. However, conjugate ...

In February 2010, a quadrivalent conjugate vaccine ... of the five major meningococcal serogroups and is immunogenic and safe when given as a four-dose schedule starting at 2 months of age ...

The spread of meningococcal ... 2 years of age, rather than delaying travel to countries with current outbreaks of meningococcal disease, as is recommended at the present time. Serogroup B ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

A vaccine against meningococcal disease or any other disease works by generating an immune response in the body against some kind of pathogen—a virus, bacterium, or some other agent that causes ...

Demand for meningococcal vaccines is increasing due to heightened awareness of meningitis outbreaks and the availability of conjugate and multivalent vaccines. Government-backed immunization programs ...

to protect against a fifth strain of meningococcal bacteria. Most adolescents receive this vaccine, though it's not yet required: Between 16 years and 23 years (preferred age 16 to 18 years) 2 ...

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.